As Recursion increased the size of the training data and the number of model parameters, the model’s performance increased, demonstrating a need for ample compute to train larger models.

Boltz-2’s development was led by the Boltz team at MIT under the supervision of Professors Regina Barzilay and Tommi Jaakkola alongside a team of researchers from MIT and Recursion.

Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to ...